Basilea Pharmaceutica Balance Sheet Health
Financial Health criteria checks 5/6
Basilea Pharmaceutica has a total shareholder equity of CHF16.8M and total debt of CHF95.7M, which brings its debt-to-equity ratio to 570%. Its total assets and total liabilities are CHF188.7M and CHF171.9M respectively.
Key information
570.0%
Debt to equity ratio
CHF 95.68m
Debt
| Interest coverage ratio | n/a |
| Cash | CHF 62.96m |
| Equity | CHF 16.79m |
| Total liabilities | CHF 171.88m |
| Total assets | CHF 188.66m |
Recent financial health updates
No updates
Recent updates
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Financial Position Analysis
Short Term Liabilities: BSLN's short term assets (CHF155.0M) exceed its short term liabilities (CHF37.8M).
Long Term Liabilities: BSLN's short term assets (CHF155.0M) exceed its long term liabilities (CHF134.1M).
Debt to Equity History and Analysis
Debt Level: BSLN's net debt to equity ratio (194.9%) is considered high.
Reducing Debt: BSLN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BSLN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BSLN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 40.5% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 09:09 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Basilea Pharmaceutica AG is covered by 25 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |